EU Approves Teclistamab Monotherapy as Earlier Treatment for Relapsed Multiple Myeloma

The European Commission has approved an expanded indication for the targeted immunotherapy teclistamab, authorizing its use as a standalone treatment for adults with relapsed or refractory multiple myeloma after just one prior therapy. The October 2026 decision shifts a powerful bispecific antibody, previously reserved for heavily pretreated patients, into the crucial second-line setting.[1][2]

Multiple myeloma is an incurable blood cancer characterized by the uncontrolled proliferation of malignant plasma cells in the bone marrow. Patients typically navigate a grueling cycle of remission and relapse, but with each successive treatment failure, the cancer mutates and becomes increasingly resistant to standard drug classes.[3]

Because the disease grows more aggressive over time, the duration of disease control shrinks with each new line of therapy. Oncologists increasingly prioritize deploying their most effective therapies at the first sign of relapse, aiming to secure a deep and durable remission before the patient's immune system becomes too exhausted to respond.[1][6]

Targeting the BCMA protein

The therapy focuses on the B-cell maturation antigen (BCMA), a protein that is universally and heavily expressed on the surface of malignant myeloma cells but largely absent from healthy tissue. This makes BCMA an ideal target for precision immunotherapies designed to hunt down cancer cells without destroying the surrounding bone marrow.[3]

Teclistamab, marketed by Johnson & Johnson as Tecvayli, is an "off-the-shelf" bispecific T-cell engager administered via subcutaneous injection. The engineered antibody features two distinct binding arms: one locks onto the BCMA protein on the myeloma cells, while the other attaches to the CD3 receptor on the body's own immune T cells.[3][6]

By binding to both targets simultaneously, the drug physically drags the patient's cytotoxic T cells into direct contact with the cancer. This forced proximity bypasses the tumor's normal evasion mechanisms, triggering the T cells to release perforin and granzymes that punch holes in the malignant cells and destroy them.[3]

Unlike CAR-T cell therapies, which also target BCMA but require extracting a patient's cells and spending weeks manufacturing a custom treatment in a laboratory, teclistamab is ready to use immediately. This logistical advantage is critical for patients with rapidly progressing disease who cannot afford to wait for custom cellular engineering.[6]

The MajesTEC-9 trial results

The regulatory expansion rests on efficacy data from the Phase 3 MajesTEC-9 trial, which evaluated teclistamab monotherapy against standard-of-care regimens. The study enrolled patients who had received between one and three prior lines of therapy, including an anti-CD38 monoclonal antibody and the immunomodulator lenalidomide.[2][3]

Participants in the control arm received investigator's choice of two standard combination regimens. These consisted of either pomalidomide, bortezomib, and the steroid dexamethasone, or a pairing of carfilzomib and dexamethasone, representing the conventional approaches to managing early relapses in European clinics.[2]

Trial results demonstrated that teclistamab reduced the risk of disease progression or death by 71 percent compared to the standard care regimens. At a median follow-up of 17.3 months, the estimated 18-month progression-free survival rate was 69.8 percent for the 296 patients receiving the bispecific antibody, compared to just 26.9 percent for the 297 patients in the control group.[2][3]

The therapy also yielded a 40 percent reduction in the overall risk of death, with 18-month overall survival rates reaching 79.2 percent versus 68.6 percent. Nearly two-thirds of patients—65.9 percent—achieved a complete response or better on teclistamab, vastly outperforming the 16.8 percent complete response rate seen with standard treatments.[2][3]

"Patients with relapsed or refractory multiple myeloma often experience shorter remissions and diminishing responses with each subsequent line of therapy, making effective treatment at first relapse increasingly important," said Cyrille Touzeau, a professor at the University Hospital of Nantes in France.[1][6]

Shifting the treatment paradigm

Touzeau noted that the authorization provides a critical new tool for hematologists managing early relapses. "The approval of teclistamab monotherapy gives physicians an additional immunotherapy option in the second-line setting, supported by significant improvements in both progression-free and overall survival," he stated.[1][6]

The drug's journey reflects a broader trend in oncology of proving efficacy in late-stage disease before moving to earlier lines. The European Commission initially approved teclistamab in August 2022, but restricted its use to patients who had exhausted at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.[2][6]

The monotherapy expansion closely follows another regulatory milestone for the drug. In August 2026, European regulators approved teclistamab in combination with daratumumab for the same second-line setting, based on the MajesTEC-3 trial which showed that the combination reduced the risk of disease progression or death by 83.4 percent.[3][6]

Having both monotherapy and combination options available at the first relapse allows clinicians to tailor their approach based on a patient's frailty, previous drug exposures, and disease aggression. It also offers an effective regimen that does not strictly require the continuous use of high-dose steroids like dexamethasone, which carry severe long-term side effects.[3]

"Today's approval marks another important step in our ambition to bring innovative immunotherapies earlier in the treatment journey for patients with multiple myeloma," said Yusri Elsayed, Global Therapeutic Area Head of Oncology at Johnson & Johnson. He emphasized that the dual approvals aim to establish teclistamab as a foundational option at first relapse.[1]